This article is more than 5 years old. Information may no longer be current.

Abramson Cancer Center becomes member institution of National Comprehensive Cancer Network

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Abramson Cancer Center at University of Pennsylvania joined the National Comprehensive Cancer Network as its 28th member institution.

This alliance of top U.S. academic cancer centers — started by 13 founding member institutions in 1995 and now comprising 1,300 experts across its member institutions — aims to improve and enable high-quality, effective and accessible care for patients with cancer.

Abramson Cancer Center’s membership includes the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Pennsylvania Hospital and Children’s Hospital of Philadelphia.

“The Abramson Cancer Center is leading the charge of the immunorevolution, with research that has led to four new FDA-approved cancer drugs this year alone,” Robert Vonderheide, MD, DPhil, director of Abramson Cancer Center, said in a press release. “We're energized to share our expertise with the NCCN, as well as for the chance to collaborate with other member institutions to ensure patients across the country are receiving the best possible care.”

Experts from NCCN member institutions work together in 53 panels to review the latest research and drug approvals and update the 73 NCCN Clinical Practice Guidelines in Oncology, which apply to 97% of cancers affecting patients in the U.S.

“The Abramson Cancer Center is a perfect fit and wonderful addition to the group of leading cancer centers that comprise NCCN,” Robert W. Carlson, MD, CEO of NCCN, said in a press release. “Penn Medicine is one of the pioneers for immunotherapy and is also at the forefront for innovative treatment approaches involving stem cell transplantation, genetics, palliative care, pediatric cancer care, pediatrics and other areas. Penn Medicine also shares NCCN's commitment to improving care for underserved populations in the United States and abroad. We look forward to working together to make sure people with cancer everywhere receive the very best evidence-based care possible.”